Economic disadvantages of palivizumab.
Smith
R A
RA
Boon
R
R
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000191:economics*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab